Patent Supported: Benefit from cutting-edge science, with our formulation bolstered by 7 micronutrient patents, including a groundbreaking patent on micronutrient protection against radiation
While use of the GLP-1 medications has skyrocketed, evidence on their long-term impact is still being assessed
Data suggests that adults taking the therapeutic dose of oral semaglutide can expect to lose approximately 15% to 16% of their body weight over 68 weeks
INTERHEART Study Investigators
Saxendas approval set a precedent in efficacy and pricing, with a cost of over $1,000 per month
25,26 Effects on Epicardial Adipose Tissue GLP1-RAs decrease the volume of epicardial adipose tissue, which is often elevated in HFpEF and is a source of proinflammatory cytokines and adipokines